The Controversy Over Ponatinib

Although ponatinib was given accelerated approval by the FDA, it was withdrawn based on evidence of serious thrombotic adverse events.

{{{error}}}

{{error}}

{{{ form.title }}}

*Required{{ field.label }}{{ field.label }}

{{ field.label }}

{{ field.label }}{{ field.additionalLabel }}

By registering you consent to the collection and use of your information to provide the products and services you have requested from us and as described in our privacy policy and terms and conditions.

CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.

Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.